Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 2/20 | 0.60 |
| ▸ | CASP3 | P42574 | 1/20 | 0.60 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | BCHE | P06276 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CFTR | P13569 | 1/20 | 0.48 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.48 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14079628 | 1.00 | CASP1 (0.60) | CASP1CASP3CASP8ALDH1A1KDM4E | |
| SCHEMBL12624640 | 0.89 | CASP1 (0.58) | CASP1CASP3CASP8ALDH1A1KDM4E | |
| SCHEMBL12529604 | 0.85 | CASP1 (0.55) | CASP1CASP3CASP8ALDH1A1KDM4E | |
| SCHEMBL927372 | 0.83 | CASP1 (0.56) | CASP1CASP3CASP8ALDH1A1KDM4E | |
| SCHEMBL12529991 | 0.81 | CASP1 (0.51) | CASP1CASP3CASP8ALDH1A1KDM4E | |
| SCHEMBL15160572 | 0.79 | ALOX15 (0.52) | CASP1CASP3CASP8ALDH1A1KDM4E | |
| SCHEMBL12944434 | 0.78 | CASP1 (0.48) | CASP1CASP3CASP8ALDH1A1KDM4E | |
| SCHEMBL12908778 | 0.78 | CASP1 (0.48) | CASP1CASP3CASP8ALDH1A1KDM4E | |
| SCHEMBL12529625 | 0.78 | CASP1 (0.48) | CASP1CASP3CASP8ALDH1A1KDM4E | |
| SCHEMBL12862811 | 0.76 | ALOX15 (0.49) | CASP1CASP3CASP8ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968716-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968716-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968716-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-28 | — | — | US | disclosed |
| US-20110003824-A1 | Caspase Inhibitors and Uses Thereof | VERTEX PHARMACEUTICALS INCORPORDTED (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003824-A1 | Caspase Inhibitors and Uses Thereof | VERTEX PHARMACEUTICALS INCORPORDTED (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003824-A1 | Caspase Inhibitors and Uses Thereof | VERTEX PHARMACEUTICALS INCORPORDTED (US) | 2011-01-06 | — | — | US | disclosed |
| US-7829561-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829561-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829561-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090023739-A1 | interleukin-1B converting enzyme inhibitors such as 3-(6,11-Dioxo-1,2,3,4-tetrahydro-pyridazino[1,2-b]phthalazin-1-carboxamido)-5-fluoro-4-oxo-pentanoic acid, that mediate cell apoptosis and inflammation, used for cell or organ preservation and the treatment of osteoarthritis and rheumatoid arthritis | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023739-A1 | interleukin-1B converting enzyme inhibitors such as 3-(6,11-Dioxo-1,2,3,4-tetrahydro-pyridazino[1,2-b]phthalazin-1-carboxamido)-5-fluoro-4-oxo-pentanoic acid, that mediate cell apoptosis and inflammation, used for cell or organ preservation and the treatment of osteoarthritis and rheumatoid arthritis | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023739-A1 | interleukin-1B converting enzyme inhibitors such as 3-(6,11-Dioxo-1,2,3,4-tetrahydro-pyridazino[1,2-b]phthalazin-1-carboxamido)-5-fluoro-4-oxo-pentanoic acid, that mediate cell apoptosis and inflammation, used for cell or organ preservation and the treatment of osteoarthritis and rheumatoid arthritis | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2009-01-22 | — | — | US | disclosed |
| EP-1289993-B9 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1289993-B9 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2008-08-20 | — | — | EP | disclosed |
| US-7407964-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-05 | — | — | US | disclosed |
| US-7407964-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1289993-B1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1289993-B1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20020045623-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023739-A1 | interleukin-1B converting enzyme inhibitors such as 3-(6,11-Dioxo-1,2,3,4-tetrahydro-pyridazino[1,2-b]phthalazin-1-carboxamido)-5-fluoro-4-oxo-pentanoic acid, that mediate cell apoptosis and inflammation, used for cell or organ preservation and the treatment of osteoarthritis and rheumatoid arthritis | IL1B, IL1RN, CASP1 | CASP1 3/4885CASP3 8/4885CASP8 78/4885 |
| US-20020045623-A1 | Caspase inhibitors and uses thereof | CASP3, CASP1, CASP2 | CASP1 2/4885CASP3 1/4885CASP8 11/4885 |
| US-20110003824-A1 | Caspase Inhibitors and Uses Thereof | CASP3, CASP2, CASP1 | CASP1 3/4885CASP3 1/4885CASP8 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.